Core Viewpoint - The company has obtained a medical device production license for its blood dialysis concentrate (dry powder) product, enabling production and market sales [1] Group 1 - The license was issued by the Gansu Provincial Drug Administration on February 5, 2026 [1] - The blood dialysis concentrate (dry powder) is used for blood dialysis treatment in acute and chronic renal failure and has been widely applied in clinical settings [1]

Core Viewpoint - The company, Longshen Rongfa, has obtained a Medical Device Manufacturing License from the Gansu Provincial Drug Administration, allowing it to produce and sell its blood dialysis concentrate (powder) products, which are essential for treating acute and chronic renal failure [1] Group 1 - The acquisition of the Medical Device Manufacturing License signifies that the company's blood dialysis concentrate (powder) products are now qualified for production and market sales [1] - Blood dialysis concentrate (powder) is widely used in clinical settings for blood dialysis treatment in patients with acute and chronic renal failure [1] - This license acquisition will facilitate the company's production and operational efforts for the blood dialysis concentrate (powder) products, enhancing its industry layout and fostering new profit growth points [1] Group 2 - The development is expected to improve the company's overall market competitiveness and has positive implications for its future growth [1]

陇神戎发公告，公司于2026年2月5日取得由甘肃省药品监督管理局核发的《医疗器械生产许可证》，许 可证编号为甘药监械生产许20260001号。本次取得《医疗器械生产许可证》标志着公司血液透析浓缩液 （干粉）产品具备生产和上市销售的资质。 ...